Stein Jeffrey

Director Stein Jeffrey purchased 50,000 shares of IDYA at $32.96, raising holdings to 54,281 shares (+1168.0%)

Stein Jeffrey, a director at IDEAYA Biosciences, executed a substantial open-market purchase of 50,000 shares at $32.96 on 2026-03-02, with a total transaction value of $1,647,890.00. This acquisition increased his shareholding from 4,281 shares to 54,281 shares—a 1168.0% increase—representing a material deepening of his ownership stake in the company. The transaction occurred at a price approximately 0.24% below the current market price of $33.04 and reflects a buy decision made while the stock trades 12.7% below its 52-week high of $37.86. Notably, this contrasts with the company's recent fundamental position: while the latest quarter showed revenue of $207,834,000.00 and net income of $119,244,000.00, the company was unprofitable over its most recent full fiscal year despite posting extraordinary revenue growth of +3024.4% year-over-year. The magnitude of the position increase and the timing relative to this financial backdrop merit investor attention to track whether the director's expanded commitment proves well-founded.

Cidara CEO Jeffrey Stein purchased 4,262 shares across 4 separate transactions (2017–2020) for $339,039.60; post-trade holdings 2,379 shares despite negative net income of $-83,233,000.00.

Jeffrey Stein, President & CEO of Cidara Therapeutics, made 4 separate open-market purchases totaling 4,262 shares for $339,039.60 with a blended average price of $79.55, accumulating to 2,379 shares post-transaction. The purchases spanned from March 2017 through November 2020, with the most recent buy at $40.01 per share in November 2020 when the stock was trading significantly below earlier acquisition prices. The company reported zero latest-quarter revenue and annual net income of $-83,233,000.00, with annual revenue declining 98.0% year-over-year, indicating severe operational distress. At his prior two same-ticker purchases (June 2024 and August 2023), only one showed a positive 90-day outcome, and his cross-ticker track record across 2 prior buys averaged +779.0% 90-day return but reflects limited transaction history. The current price of $221.38 is near the 52-week high, suggesting material appreciation since the earlier tranches despite the company's deteriorating fundamentals.